Successful short-term peg-interferon monotherapy for chronic hepatitis

April 8, 2010

The standard duration of interferon therapy for chronic hepatitis C could be shortened according to the virological and clinical status of each patient. A research group in Japan proposed a new concept, "immediate virological response (IVR)", and showed that short-term peg-interferon monotherapy was highly effective for patients with low viral load and IVR. Hepatitis C virus was eliminated in 92.1 percent of patients.

The efficacy of interferon (IFN) therapy depends on the hepatitis C virus (HCV) genotype, pretreatment viral load and early viral kinetics. Thus, IFN therapy must be individualized and optimized according to the virological and clinical status of each patient.

A research article to be published on March 28, 2010 in the addresses this question. Dr. Masumoto and his colleagues at Iizuka Hospital proposed the new concept of early viral kinetics in peg-interferon (PEG-IFN) therapy. They defined the "immediate virological response (IVR)" as the loss of serum HCV RNA 7 days after the first administration of PEG-IFN, and scheduled a 12-week treatment course of PEG-IFN for 38 patients who had low pretreatment HCV RNA load and exhibited IVR. As a result, 35 patients (92.1%) achieved sustained virological response (SVR); the elimination of HCV.

Establishing the minimum and yet sufficient IFN therapy period is essential in terms of financial efficiency and for reducing the risk of adverse events. The results of this study provide an important suggestion which will allow future investigations to optimize the treatment regimen of IFN therapy for chronic , especially for the patients who exhibit fast virological response to IFN. IVR, the new concept proposed in this study, should be a simple and useful indicator of early viral kinetics to predict the high probability of SVR.

More information: Yada M, Masumoto A, Yamashita N, Motomura K, Koyanagi T, Sakamoto S. Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C. World J Gastroenterol 2010; 16(12): 1506-1511 www.wjgnet.com/1007-9327/full/v16/i12/1506.htm

Related Stories

Recommended for you

New way of screening potential treatments for tuberculosis

March 29, 2017

Scientists from LSTM's Research Centre for Drugs and Diagnostics (RCDD) have described in a paper published today in Scientific Reports, a new way of screening potential treatments for Tuberculosis (TB) which may assist in ...

Discovery may help patients beat deadly pneumonia

March 28, 2017

Researchers have found that a hormone responsible for controlling iron metabolism helps fight off a severe form of bacterial pneumonia, and that discovery may offer a simple way to help vulnerable patients.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.